Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | QPCT | Q16769 | 1/20 | 0.58 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13546992 | 0.89 | CYP3A4 (0.60) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL17481128 | 0.86 | CYP3A4 (0.82) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL9058710 | 0.85 | CYP3A4 (0.68) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL13033285 | 0.81 | CYP3A4 (0.74) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL18381205 | 0.81 | CYP3A4 (0.74) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL17481134 | 0.81 | CYP3A4 (0.78) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL17483163 | 0.81 | CYP3A4 (0.78) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL17483288 | 0.80 | QPCT (0.66) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL25670592 | 0.80 | CYP3A4 (0.72) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL18381362 | 0.80 | CYP3A4 (0.64) | CYP3A4CYP2D6TSHRCYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268312-B2 | Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof | IMMUNOMEDICS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120107235-A1 | Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof | IMMUNOMEDICS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8097252-B2 | Methods and compositions for administering therapeutic and diagnostic agents | IMMUNOMEDICS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8084029-B2 | Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof | IMMUNOMEDICS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8017736-B2 | Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof | IMMUNOMEDICS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017736-B2 | Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof | IMMUNOMEDICS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-7951369-B2 | Chimeric, human and humanized anti-granulocyte antibodies and methods of use | IMMUNOMEDICS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20110117010-A1 | Methods and Compositions for Administering Therapeutic and Diagnostic Agents | IMMUNOMEDICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7943343-B2 | Production and use of novel peptide-based agents for use with bi-specific antibodies | IMMUNOMEDICS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943343-B2 | Production and use of novel peptide-based agents for use with bi-specific antibodies | IMMUNOMEDICS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7387772-B1 | Chimeric, human and humanized anti-CSAP monoclonal antibodies | IMMUNIMEDICS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20080089838-A1 | Chimeric, Human and Humanized Anti-CSAP Monoclonal Antibodies | IMMUNOMEDICS, INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080089838-A1 | Chimeric, Human and Humanized Anti-CSAP Monoclonal Antibodies | IMMUNOMEDICS, INC. | 2008-04-17 | — | — | US | disclosed |
| US-7300655-B2 | Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof | IMMUNOMEDICS, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070183970-A1 | Chimeric, human and humanized anti-granulocyte antibodies and methods of use | IMMUNOMEDICS, INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070142296-A1 | D-amino acid peptides | IMMUNOMEDICS, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070048227-A1 | MULTISPECIFIC NONCOVALENT COMPLEXES FOR DELIVERY OF THERAPEUTICS | IMMUNOMEDICS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070048227-A1 | MULTISPECIFIC NONCOVALENT COMPLEXES FOR DELIVERY OF THERAPEUTICS | IMMUNOMEDICS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-7172751-B2 | Immunological reagents for therapeutic use, for example, in radioimmunotherapy (RAIT), and diagnostic use, for example, in radioimmunodetection (RAID) and magnetic resonance imaging | IMMUNOMEDICS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-7172751-B2 | Immunological reagents for therapeutic use, for example, in radioimmunotherapy (RAIT), and diagnostic use, for example, in radioimmunodetection (RAID) and magnetic resonance imaging | IMMUNOMEDICS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107235-A1 | Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof | INHA, HDGF, IGSF11 | CYP3A4 3808/4885CYP2D6 4049/4885TSHR 1778/4885 |
| US-20070048227-A1 | MULTISPECIFIC NONCOVALENT COMPLEXES FOR DELIVERY OF THERAPEUTICS | CNDP2, DNPEP, CD47 | CYP3A4 673/4885CYP2D6 139/4885TSHR 3792/4885 |
| US-20110117010-A1 | Methods and Compositions for Administering Therapeutic and Diagnostic Agents | CD47, FCGR3B, HAVCR2 | CYP3A4 4873/4885CYP2D6 4791/4885TSHR 1681/4885 |
| US-20070142296-A1 | D-amino acid peptides | DAO, NRDC, ARGLU1 | CYP3A4 4204/4885CYP2D6 2633/4885TSHR 88/4885 |
| US-20070183970-A1 | Chimeric, human and humanized anti-granulocyte antibodies and methods of use | CSF3R, CCR3, FCGR3B | CYP3A4 4390/4885CYP2D6 4018/4885TSHR 2795/4885 |
| US-20080089838-A1 | Chimeric, Human and Humanized Anti-CSAP Monoclonal Antibodies | CHP1, CLSPN, CYTH3 | CYP3A4 2408/4885CYP2D6 2480/4885TSHR 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.